Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The Medicines Company (MDCO - Analyst Report) recently announced that patient enrollment for its pivotal phase III CHAMPION PHOENIX trial is expected to finish in the fourth quarter of 2012. The study is evaluating cangrelor for the prevention of platelet activation and aggregation when oral therapy is not feasible or desirable.

The Medicines Company’s said that the study’s independent Data Safety Monitoring Board (DSMB) recommended a sample size of 10,900 patients for the trial. The DSMB earlier conducted a pre-specified interim analysis with around 7,700 patients from the trial.

Besides cangrelor, The Medicines Company has two late stage candidates. The company is developing oritavancin, a semi-synthetic lipoglycopeptide antibiotic candidate. The other candidate is MDCO-157, a Captisol-enabled intravenous (IV) formulation of clopidogrel (the active ingredient in Plavix).

While oritavancin became a part of the company’s pipeline through its acquisition of Targanta Therapeutics in February 2009, The Medicines Company entered into a licensing agreement with Ligand Pharmaceuticals (LGND - Snapshot Report) in June 2011 under which it acquired exclusive worldwide rights to MDCO-157.

The resolution of the Angiomax patent extension case was a major boost for The Medicines Company. The company's settlement agreements with Teva (TEVA - Analyst Report) and APP regarding Angiomax are also positive events. We are also pleased to see the company's progress with its pipeline.

Moreover, we are pleased to see that management is actively pursuing in-licensing deals and acquisitions to drive growth. The AstraZeneca (AZN - Analyst Report) deal is another smart move by the company. However, we believe all these positive developments are already factored into the stock price.

We currently have a Neutral recommendation on The Medicines Company, which carries a Zacks #3 Rank (short-term Hold rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%